faldaprevir
Small moleculeexperimental
Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available. — Wikipedia
Clinical trial activity
49 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
30
Phase 2
19
Phase 3
10
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT02182271)
Timeline
Indications
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O- Mol. weight
- 869.84 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFaldaprevir ↗
- ChEMBLCHEMBL1241348 ↗
Also known as
- bi201335
- bi201335
- bi201335
- bi 201335
- bi 201335
- bi 201335
- bi 201335
- bi-201335
- bi-201335
- bi-201335
- faldaprevir
- faldaprevir
- faldaprevir
- faldaprevir
- faldaprevir
- faldeprevir
- n-((cyclopentyloxy)carbonyl)-3-methylvalyl-4-((8-bromo-7-methoxy-2-(2-((2-methylpropanoyl)amino)-1,3-thiazol-4-yl)quinolin-4-yl)oxy)-n-(1-carboxy-2-ethenylcyclopropyl)prolinamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02716428 | Phase 2 | May 1, 2016 | Auckland Clinical Studies, Southern California Research Center, Trek Therapeutics, PBC |
| NCT02593162 | Phase 2 | Oct 1, 2015 | Southern California Research Center, Trek Therapeutics, PBC |
| NCT02114671 | Phase 1 | Apr 1, 2014 | Boehringer Ingelheim |
| NCT02016625 | Phase 1 | Dec 1, 2013 | Boehringer Ingelheim |
| NCT01941615 | Phase 1 | Nov 1, 2013 | Boehringer Ingelheim |
| NCT01957657 | Phase 1 | Oct 1, 2013 | Boehringer Ingelheim |
| NCT01965431 | Phase 1 | Oct 1, 2013 | Boehringer Ingelheim |
| NCT01859962 | Phase 2 | May 1, 2013 | Boehringer Ingelheim, Presidio Pharmaceuticals |
| NCT01858961 | Phase 3 | May 1, 2013 | Boehringer Ingelheim |
| NCT01830127 | Phase 2 | Apr 1, 2013 | Boehringer Ingelheim |
| NCT01821937 | Phase 1 | Mar 1, 2013 | Boehringer Ingelheim |
| NCT01795937 | Phase 1 | Feb 1, 2013 | Boehringer Ingelheim |
| NCT01785160 | Phase 1 | Feb 1, 2013 | Boehringer Ingelheim |
| NCT01764945 | Phase 1 | Jan 1, 2013 | Boehringer Ingelheim |
| NCT01732796 | Phase 3 | Dec 1, 2012 | Boehringer Ingelheim |
| NCT01728324 | Phase 3 | Nov 1, 2012 | Boehringer Ingelheim |
| NCT01737996 | Phase 1 | Nov 1, 2012 | Boehringer Ingelheim |
| NCT01704846 | Phase 1 | Oct 1, 2012 | Boehringer Ingelheim |
| NCT01694706 | Phase 1 | Sep 1, 2012 | Boehringer Ingelheim |
| NCT01608737 | Phase 3 | Sep 1, 2012 | Boehringer Ingelheim |
Showing 20 of 49 trials
Page 1 / 3
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 47 | 46 | 3 | 2004 |
| Southern California Research Center | For profit | 2 | 0 | 1 | 2015 |
| Trek Therapeutics, PBC | For profit | 2 | 2 | 1 | 2015 |
| Auckland Clinical Studies | For profit | 1 | 0 | 1 | 2016 |
| Presidio Pharmaceuticals | For profit | 1 | 1 | 1 | 2013 |
5 organizations
Page 1 / 1